Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes



: White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators

Publisher: MASSACHUSETTS MEDICAL SOC

: 2013

: New England Journal of Medicine

: NEW ENGLAND JOURNAL OF MEDICINE

: NEW ENGL J MED

: 14

: 369

: 14

: 1327

: 1335

: 9

: 0028-4793

DOI: https://doi.org/10.1056/NEJMoa1305889


ConclusionsAmong patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.)



Last updated on 2024-26-11 at 21:27